期刊
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
卷 243, 期 -, 页码 -出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2022.114706
关键词
Human DNA topoisomerase II?; Catalytic inhibitor; Antitumor
资金
- NSFC [81273384, 90913024]
- Program for Changjiang Scholars and Innovative Research team in University [IRT_17R68]
Fifty-eight pinosylvin derivatives were designed and synthesized as topoisomerase II (TopoII) inhibitors, with the most potent compound F2 showing high inhibitory efficacy against TopoII and strong antitumor activities against multiple human cancer cell lines. F2 also exhibited less cytotoxicity against normal cells compared to the chemotherapeutic agent VP-16.
Human DNA topoisomerase II (TopoII) is highly correlated with cell proliferation, and involved in tumor biogenesis and development. The classic chemotherapeutic agents etoposide (VP-16) and adriamycin (ADR) targeting TopoII are wildly used in clinical applications. Herein, fifty-eight pinosylvin (1,2-diphenylethene) derivatives as TopoII inhibitors were designed and synthesized through three generations of structural optimizations on the basis of the structure of the initial hit A1 from in-house chemical library. The most potent compound F2 showed high in vitro inhibitory efficacy against TopoII (IC50 alpha 3.8, beta 10.1 mu M), compared to that of VP-16 (IC50 alpha 110.0, beta 36.1 mu M) for pBR322 DNA relaxation with no evident TopoII poisons in DNA cleavage assay. Meanwhile, F2 exhibited strong antitumor activities against human cancer cell lines HeLa, HCT-116, PC-3, MDA-MB-231, HepG2 and A549 (IC(50 )0.1-0.3 mu M), compared to that of VP-16 (IC50 1.5-15.1 mu M). F2 showed less cytotoxicity against normal murine cell line CCL-226 (IC50 > 50 mu M) than that of VP-16 (IC50 20.8 mu M). The selectivity index of F2 and VP-16 are larger than 52.1 and 1.3-26.2 in cell lines, respectively. Additionally, F2 exhibited potent potency in apoptosis induction and cell cycle arrest in HepG2 cells. These results provide a promising strategy and good starting point for the development of potent TopoII inhibitors as antitumor agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据